Does ampicillin-sulbactam cause false positivity of (1,3)-beta-D-glucan assay? A prospective evaluation of 15 patients without invasive fungal infections

Mycoses

Volumn 55, Issue 4, 2012, Pages 366-371

  Metan, Gokhan ^a   Agkus, Cigdem ^a   Nedret Koc, A ^a   Elmali, Ferhan ^a   Finkelman, Malcolm A ^b  

^a ERCIYES UNIVERSITY   (Turkey)

^b NONE

Author keywords

(1,3) beta D glucan; Ampicillin sulbactam; Aspergillus galactomannan antigen; False positivity

Indexed keywords

BETA 1,3 GLUCAN; DUOBAKTAM; ECZACIBASI; GALACTOMANNAN; SULTAMICILLIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLUS; ASPIRATION PNEUMONIA; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EVALUATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE RESULT; FEMALE; HUMAN; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STATISTICAL SIGNIFICANCE; SYSTEMIC MYCOSIS; URINARY TRACT INFECTION; WOUND DRESSING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPICILLIN; ANTI-INFECTIVE AGENTS; ANTIGENS, FUNGAL; BETA-GLUCANS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOSES; SULBACTAM; YOUNG ADULT;

ASPERGILLUS; ASPERGILLUS GALACTOMANNAN;

EID: 84862255446     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2011.02131.x     Document Type: Article

References (34)

1. Guarner J, Brant ME. Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev 2011; 24: 247-80.
2. Kedzierska A, Kochan P, Pietrzyk A, Kedzierska J. Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1, 3)-β-D-glucan antigens. Eur J Clin Microbiol Infect Dis 2007; 26: 755-66.
3. Sulahian A, Touratier S, Ribaud P. False-positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003; 349: 2366-7.
4. Adam O, Auperin A, Wilquin F, Bourhis JH, Gachot B, Chachaty E. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 2004; 38: 917-20.
5. Viscoli C, Machetti M, Cappellano P et al. False-positive galactomannan Platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004; 38: 913-6.
6. Tanriöver MD, Metan G, Altun B, Hasçelik G, Uzun O. False positivity for Aspergillus antigenemia related to the administration of piperacillin/tazobactam. Eur J Intern Med 2005; 16: 489-91.
7. Penack O, Rempf P, Graf B, Thiel E, Blau IW. False-positive Aspergillus antigen testing due to application of piperacillin/tazobactam-is it still an issue? Diagn Microbiol Infect Dis 2008; 60: 117-20.
8. Metan G, Agkus C, Buldu H, Koc AN. The interaction between piperacillin/tazobactam and assays for Aspergillus galactomannan and (1, 3)-beta-D-glucan in patients without risk factors for invasive fingal infections. Infection 2010; 38: 217-21.
9. Xavier MO, Pasqualotto AC, Aquino VR, Sukiennik TC, Severo LC. Braz J Infect Dis 2009; 13: 353-5.
10. Zandijk E, Mewis A, Magerman K, Cartuyvels R. False-positive results by the platelia Aspergillus galactomannan antigen test for patients treated with amoxicillin-clavulanate. Clin Vaccine Immunol 2008; 15: 1132-3.
11. Yucesoy M, Ergon MC. Investigation of Aspergillus galactomannan levels in antimicrobial agents. Mikrobiyol Bul 2007; 41: 565-70.
12. Fortún J, Martín-Dávila P, Alvarez ME et al. False-positive results of Aspergillus galactomannan antigenemia in liver transplant recipients. Transplantation 2009; 87: 256-60.
13. Marty FM, Lowry CM, Lempitski SJ, Kubiak DW, Finkelman MA, Baden LR. Reactivity of 1, 3-beta-d-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother 2006; 50: 3450-3.
14. Mennink-Kersten MA, Warris A, Verweij PE. (1, 3)-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med 2006; 354: 2834-5.
15. Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A. Contribution of the 1, 3-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2008; 46: 1009-13.
16. Maertens JA, Klont R, Masson C et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 2007; 44: 1329-36.
17. Orlopp K, von Lilienfeld-Toal M, Marklein G et al. False positivity of Aspergillus galactomannan Platelia ELISA because of piperacillin-tazobactam treatment. Does it represent a clinical problem. J Antimicrobial Chemother 2008; 62: 1109-12.
18. Lode HM. Rational antibiotic therapy and the position of ampicillin-sulbactam. Int J Antimicrob Agent 2008; 32: 10-28.
19. Ansorg R, Van den Boom R, Rath PM. Detection of Aspergillus galactomannan antigen in foods and antibiotics. Mycoses 1997; 40: 353-7.
20. Tomita Y, Sugimoto M, Kawano O, Kohrogi H. High insidence of false-positive Aspergillus galactomannan test results in patient with aspiration pneumonia. J Am Geriatr Soc 2009; 57: 935-6.
21. Heyland D, Jiang X, Day AG, Laverdiere M. Serum beta-D-glucan of critically ill patients with ventilator-associated pneumonia: Preliminary observations J Crit Care 2011; 26: 536. e1-9.
22. Marty FM, Koo S. Role of 1, 3-beta-D-glucan in the diagnosis of invasive aspergillosis. Med Mycol 2009; 47(Suppl 1): S233-40.
23. Kanomori H, Kanemitsu K, Miyasaka T et al. Measurement of (1, 3)-beta-D-glucan derived from different gauze types. Tohoku J Exp Med 2009; 217: 117-21.
24. Shupp JW, Petraitiene R, Jaskille AD et al. Early serum (1, 3)-β-D-Glucan levels in patients with burn injury. Mycoses. 2011. doi:
25. Mohr JF, Sims C, Paetznick V et al. Prospective survey of (1, 3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J Clin Microbiol 2011; 49: 58-61.
26. Racil Z, Kocmanova I, Lengerova M et al. Difficulties in using (1, 3)-beta-D-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies - high frequency of false-positive results and their analysis. J Med Microbiol 2010; 59: 1016-22.
27. Laroche C, Michaud P. New developments and prospective applications for beta-(1, 3)-glucans. Recent Pat Biotechnol 2007; 1: 59-73.
28. Davis SC, Perez R. Cosmeceuticals and natural products: wound healing. Clin Dermatol 2009; 27: 502-6.
29. Iossifova Y, Reponen T, Sucharew H, Succop P, Vesper S. Use of (1, 3)-beta-D-glucan concentrations in dust as a surrogate method for estimating specific fungal exposures. Indoor Air 2008; 18: 225-32.
30. Lee T, Grinshpun SA, Kim KY, Iossifova Y, Adhikari A, Reponen T. Relationship between indoor and outdoor airborne fungal spores, pollen, and (1, 3)-beta-D-glucan in homes without visible mold growth. Aerobiologia 2006; 22: 227-36.
31. Nagano Y, Walker J, Loughrey A et al. Identification of airborne bacterial and fungal species in the clinical microbiology laboratory of a university teaching hospital employing ribosomal DNA (rDNA) PCR and gene sequencing techniques. Int J Environ Health Res 2009; 19: 187-99.
32. Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. Evaluation of a (1, 3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43: 5957-62.
33. Mennink-Kersten MA, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of (1, 3)-beta-d-glucan assay reactivity. Clin Infect Dis 2008; 46: 1930-1.
34. Metan G, Koc AN, Agkus C, Kaynar LG, Alp E, Eser B. Can bacteraemia lead to false-positive results in (1, 3)-beta-d-glucan test? Analysis of 83 bacteraemia episodes in high-risk patients for invasive fungal infections. Rev Iberoam Micol 2011. doi:.